Cognition Therapeutics presents zervimesine advancement toward registrational development

Cognition Therapeutics presented investigational oral therapy zervimesine for DLB psychosis at Jefferies Global Healthcare Conference, advancing toward registrational clinical development. The company is progressing its lead candidate through clinical trials with expectations to replicate initial positive results in later-stage studies.